| Sep 23 |
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
|
| Sep 11 |
FDA grants breakthrough therapy status to Arrowhead’s plozasiran
|
| Sep 10 |
ARWR: PALISADE Phase 3 Results Published in NEJM…
|
| Sep 10 |
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
|
| Sep 3 |
Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug
|
| Sep 3 |
Arrowhead to file NDA after pivotal rare disease trial meets all endpoints
|
| Sep 2 |
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
|
| Aug 22 |
ARWR: Two Obesity Assets to Enter the Clinic in 2025…
|
| Aug 21 |
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
|
| Aug 16 |
Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance
|
